Plunkett Research Online: AC Immune

AC IMMUNE (ACIU:NAS) Company Profile, Corporate Revenues, Growth, Market Size, Analysis, Business Forecasts, Market Share, Metrics, SWOT

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurod.....



AC Immune
Ticker: ACIU
Exchange: NAS
Parent Company:
Year Established:
Employees:
Fiscal Year Ends in

Phone: 41 216939121
Fax: 41 216939120
Address: EPFL Innovation Park
Building B
Lausanne, 1015 Switzerland

Map
Types Of Business
Industry Ranks

Industry NAICS code:


Ranks not available
Contacts Description

AC Immune SA is a clinical-stage biopharmaceutical company that focuses on neurodegenerative diseases. The company uses its proprietary technology platforms to discover, design, and develop novel proprietary small molecules, antibodies, and vaccines for prevention, diagnosis, and treatment of neurod.....See More See More

Auditor: PricewaterhouseCoopers SA
Legal Advisor:
$USD, In whole numbers,
except marked * or %
2019 2018 2017 2016 2015 2014
Financials
    Revenue
    Cost of Revenue
    Gross Margin %
    R&D Expense
    Operating Income
    Operating Margin %
    SGA Expense
    Net Income
    Earnings Per Share
    Dividends
    Book Value Per Share
    Operating Cash Flow
    Capital Expenditure
    Free Cash Flow
Profitability
    EBITDA
    Return on Assets %
    Return on Equity %
    Net Margin %
    Assets Turnover
    Financial Leverage
Brands, Divisions and Affiliates Top Salaries
Other Thoughts Corporate Culture

Apparent Female Officers or Directors: